AraC-based pharmacotherapy of chronic myeloid leukaemia

Bibliography

• CHRONIC MYELOID LEUKEMIA TRIALISTS COLLABORATIVE GROUP: Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. j Natl. Cancer Inst. (1997) 89(21):1616–1620.
   PubMedGoogle Scholar
• ••Important meta-analysis demonstrating asignificant prolongation of survival in IFN-treated CML patients compared with conventional chemotherapy.
   Google Scholar
• SILVER RT, WOOLF SH, HEHLMANN R etal.: An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood (1999) 94(5):1517–1536.
   Google Scholar
• ••Excellent review on evidence-basedtreatment options in CML.
   Google Scholar
• HEHLMANN R, ANSARI H, HASFORD J et al.: Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronicmyeloid leukaemia (CML)-Study Group. Br. J Haematol. (1997) 97(1):76–85.
   PubMedGoogle Scholar
• •Important paper demonstrating the impact of risk profile on survival in CML.
   Google Scholar
• HASFORD J, PFIRRMANN M, HEHLMANN R et al.: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. j Nati Cancer Inst. (1998) 90(11):850–858.
   Google Scholar
• •Improved prognostic score for IFN-treated CML patients.
   Google Scholar
• HASFORD J FOR THE CML PROGNOSTIC FACTORS PROJECT GROUP: Prognosis of patients with CML: updated results of the collaborative CML prognostic factors group. Blood (2000) 94\(Supp1.1):546a.
   Google Scholar
• ROSTI G ON BEHALF OF THE EUROPEAN INVESTIGATOR GROUP ON INTERFERON IN CML (EICML): Complete cytogenetic responders and long term survivors. Haematologica (2000) 85(Suppl.):5–6.
   Google Scholar
• GUILHOT F, CHASTANG C, MICHALLET M et al.: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl. j Med. (1997) 337(4):223–229.
   PubMed Web of Science ®Google Scholar
• ••First and largest randomised trialcomparing IFN vs. IFN + AraC in chronic-phase CML.
   Google Scholar
• UEDA T, MATSUYAMA S, YAMAUCHI T et al.: Clinical pharmacology of intermediate and low-dose cytosine arabinoside (ara-C) therapy in patients with hematologic malignancies. Adv. Exp. Med. Biol. (1998) 431:647–651.
   PubMedGoogle Scholar
• LINDAUER M, DOMKIN D, DOHNER H et al.: Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemia. Br Haematol. (1999) 106(4):1013–1039. la SOKAL JE, LEONG SS, GOMEZ GA: Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia. Cancer (1987) 59(1):197–202.
   Google Scholar
• SOKAL JE, GOCKERMAN JP, BIGNER SH: Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia. Leuk. Res. (1988) 12 (6):453–458.
   PubMedGoogle Scholar
• RICHMAN CM, SLAPAK CA, TOH B: Interferon protects normal human granulocyte/macrophage colony-forming cells from Ara-C cytotoxicity. I Biol. Response Modifiers (1990) 9(6)570–575.
   Google Scholar
• ROBERTSON MJ, TANTRAVAHI R, GRIFFIN JD et al.: Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low dose cytarabine. Am. Hematol (1993) 43(2):95–102.
   PubMedGoogle Scholar
• GUILHOT E DREYFUS B, BRIZARD A, HURET JL, TANZER J. Cytogenetic remission in chronic myelogenous leukemia using interferon a2a and hydroxyurea with or without low-dose cytosine-arabinoside. Leuk. Lymph. (1991) 4:549–556.
   Google Scholar
• THALER J, FLUCKINGER T, HUBER Heta].: Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside. Leuk. Res. (1993) 17(8):711–715.
   Google Scholar
• ARTHUR CK, MA DD: Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematol. (1993) 89\(Supp1.1):15–21.
   Google Scholar
• THALER J, HILBE W, APFELBECK U etal.: Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center Phase II study. Leuk. Res. (1997) 21(1):75–80.
   Google Scholar
• KANTARJIAN HM, KEATING MJ, ESTEY EH et al: Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-a and low dose cytarabine. Chi]. arca (1992) 10(5):772–778.
   Google Scholar
• •Study demonstrating feasibility and safety of the combination of IFN + AraC in a considerable number of patients in advanced stages of CML.
   Google Scholar
• FERRAJOLI A, LIBERATI AM, CARICCHI P et al.: Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients. Eur. Haemtol (1995) 55(3):184–188.
   PubMedGoogle Scholar
• GUILHOT F, GUERCI A, FIERE D etal.: The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. Bone Marrow Transplant (1996) 17\(Supp1.3):29–31.
   Google Scholar
• ROSTI G, BONIFAZI F, DE VIVO A et al.: Cytarabine increases karyotypic response and survival in IFNa treated chronic myelogenous leukemia patients: results of a national prospective randomized trial of the Italian Cooperative Study Group in CML. Blood (1999) 94\(Supp1.1):600a.
   Google Scholar
• GILES FJ, SHAN J, CHEN S et al.: A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study. Leuk. Lymph. (2000) 37(3-4):367–377.
   PubMed Web of Science ®Google Scholar
• GUILHOT F: The use of interferon-a with or without cytarabine and other new agents for the treatment of chronic myeloid leukemia. Educational Book. 5th Congress of the European Haematology Association. Birmingham, UK (25-28th June 2000).
   Google Scholar
• ROSTI G, TRABACCHI E, BONIFAZI F, DE VIVO A, TURA S: Interferon-a and Ara-C. In: Chronic Myeloid Leukemia: Biology and Treatment. AM Carella, GQ Daley, CJ Eaves, JM Goldman, R Hehlmann (Eds.). Dunitz, Oxford (2001). (In Press).
   Google Scholar
• •Excellent review concerning treatment of CML with IFN + AraC.
   Google Scholar
• KANTARJIAN HM, O'BRIEN S, SMITH TL et al.: Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. I Chi]. arca (1999) 17(1):284–292.
   Google Scholar
• •Results of a high number of chronic-phase CML patients treated with IFN + AraC.
   Google Scholar
• KANTARJIAN HM, TALPAZ M, SMITH TL et al: Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. j CBI]. arca (2000) 18(20):3513–3521.
   Google Scholar
• TALPAZ M, CORTES J, O'BRIEN S et al: PEG-Interferon a-2A (Pegasys) with or without cytarabine in patients with relapsed or refractory chronic phase CML. Blood (2000) 94\(Supp1.1):736a.
   Google Scholar
• THIESING JT, OHNO-JONES S, KOLIBABA KS, DRUKER BJ: Efficiacy of an ABL tyrosine kinase inhibitor in conjunction with other anti-neoplastic agents against BCR-ABL positive cells. Blood (1999) 94\(Suppl. 1):100a.
   Google Scholar
• TOPALY J, ZELLER WJ, FRUEHAUF S: Synergistic activity of STI571 with chemotherapeutic drugs and irradiation. Blood (2000) 94\(Suppl. 1):736a.
   Google Scholar
• SCAPPINI B, ONIDA F, KANTARJIAN H et al: In vitro effects of 5TI571-containing drug combinations on growth of Ph-positive myelogenous leukemia-derived cells. Blood (2000) 94\(Supp1.1):99a.
   Google Scholar
• KANTARJIAN H, SAWYERS C, HOCHHAUS A et al: Phase II study of STI571, a tyrosine kinase inhibitor, in patients (pts.) with resistant or refractory Philadelphia-chromosome positive chronic myeloid leukemia (Ph+CML). Blood (2000) 94\(Supp1.1):470a.
   Google Scholar
• SAWYERS C, HOCHHAUS A, FELDMAN E et al.: A Phase II study to determine the safety and antileukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis. Blood (2000) 94\(Supp1.1):503a.
   Google Scholar
• TALPAZ M, SILVER RT, DRUKER B et al.: A Phase II study of 5TI571 in adult patients with Philadelphia-chromosome positive chronic myeloid leukemia in accelerated phase. Blood (2000) 94\(Supp1.1):469a.
   Google Scholar
• SAGAYADAN GE, WIERNIK PH, SUN N et al: Effect of retinoic acid and interferon alpha on granulocyte-macrophage colony forming cells in chronic myeloid leukemia: increased inhibition by all-trans- and 13-cis-retinoic acids in advanced stage disease. Leuk. Res. (1994) 18(10):741–748.
   PubMedGoogle Scholar
• ZHENG A, SAVOLAINEN ER, KOISTINEN P et al.: All-trans retinoic acid combined with interferon-alpha effectively inhibits granulocyte-macrophage colony formation in chronic myeloid leukemia. Leuk Res. (1996) 20(3):243–248.
   PubMedGoogle Scholar
• MAHON FX, CHAHINE H, BARBOT C et al.: All-trans retinoic acid potentiates the inhibitory effects of interferon alpha on chronic myeloid leukemia progenitors in vitro. Leukemia (1997) 11(5):667–673.
   PubMedGoogle Scholar
• SACCHI S, KANTARJIAN HM, FREIREICH EJ et al.: Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. Leuk. Lymph. (1999) 35(5-6):483–489.
   PubMed Web of Science ®Google Scholar
• RUSSO D, MARIN L, BERTONE A, TIRIBELLI M, TESTONI N, MARTINELLI G: Pilot study of combined therapy with interferon-alpha, arabinosyl cytosine and all-trans retinoic acid in patients with chronic myeloid leukemia in the chronic phase. Haematologica (1999) 84(2):185–187.
   PubMedGoogle Scholar
• UEDA T, KAMIYA K, URASAKI Y et al: Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res. (1994) 54(1):109–113.
   PubMedGoogle Scholar
• BRAESS J, FREUND M, HANAUSKE A et al.: Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma-phase I/II studies and pharmacokinetics. Leukemia (1998) 12(10):1618–1626.
   PubMedGoogle Scholar
• GUILHOT F, MALOISEL F, GUYOTAT D etal.: A Phase II study to assess efficacy and safety of Interferon alpha 2b (IFN) in combination with oral cytarabine ocfosfate (YNK01) in patients with chronic myelogenous leukemia (CML). Blood (1998) 92\(Supp1.1):2585a.
   Google Scholar
• CERVANTES E SUREDA A, BRUNET S, HERNANDEZ-BOLUDA JC, MARTINO R, MONTSERRAT E: Interferon plus oral Ara-C in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to Interferon. Haeamatologica (2000) 85(Suppl.):16.
   Google Scholar
• KALMANTIS T, ANAGNOSTOPOULOS N, ANARGIOU C et al: Preliminary report on the CML-GIII-1/97 protocol for the treatment of chronic myelogenous leukaemia (CML) with interferon (IFN) and the per os Ara-C derivative YNK01 plus hydroxyurea (HU). Blood (2000) 94\(Supp1.1):737a.
   Google Scholar
• KUHR T, EISTERER W, APFELBECK U et al: Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study. Leuk. Res. (2000) 24(7):583–587.
   PubMedGoogle Scholar
• MOLLEE P, TAYLOR K, ARTHUR C et al.: A Phase II study of interferon alpha (IFN) and intermittent oral cytarabine (YNK01) in the treatment of newly diagnosed chronic myeloid leukemia (CML). Blood (2000) 94\(Supp1.1):545a.
   Google Scholar
• TRABACCHI E, ROSTI E, BONIFAZI F etal.: IFN and YNK01: Results of a ICSG on CML protocol. Haematologica (2000) 85(Suppl.):29.
   Google Scholar